AI peptide platform Position ProteinQure as a cutting-edge AI-driven platform for peptide drug design with validated collaborations among top pharma players. Target potential partners seeking advanced computational methods to expand chemical space and accelerate early discovery for extracellular targets.

Phase I lead Leverage PQ203 entering Phase I trials for TOP1-resistant triple-negative breast cancer to identify collaboration, licensing, or co-development opportunities around precision therapies for hard-to-treat cancers and oncology peptide delivery approaches.

Funding momentum Capitalize on recent multi-source funding from federal and genome-focused programs to demonstrate strong government-backed validation and upside in AI-powered drug delivery platforms. Use funding milestones to engage strategic investors and potential co-funding pharma deals.

siRNA CNS delivery Highlight internal programs for tissue-specific payload delivery and siRNA delivery to the CNS as a differentiator. Present partnership pitches to biotech firms seeking targeted CNS therapeutics or next-generation delivery technologies to expand their pipeline.

Scaling partnerships Emphasize proven collaborations with four of the top 25 pharma companies and the ability to access large chemical space with non-canonical building blocks. Target large biotechs and pharma companies looking to augment their R&D with AI-enabled design and rapid lead optimization.